Pembrolizumab monotherapy in metastatic triple-negative breast cancer

Lancet Oncol. 2021 Apr;22(4):415-417. doi: 10.1016/S1470-2045(21)00019-X. Epub 2021 Mar 4.

Authors

Eitan Amir¹, David W Cescon²

Affiliations

¹ Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, ON M5G 2M9, Canada. Electronic address: eitan.amir@uhn.ca.
² Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, ON M5G 2M9, Canada.

PMID: 33676605
DOI: 10.1016/S1470-2045(21)00019-X

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Neoadjuvant Therapy
Triple Negative Breast Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab